Phosphatidic acid and lipid-sensing by mTOR

Polak, 2009, mTOR and the control of whole body metabolism, Curr. Opin. Cell Biol., 21, 209, 10.1016/j.ceb.2009.01.024 Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016 Sengupta, 2010, Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress, Mol. Cell, 40, 310, 10.1016/j.molcel.2010.09.026 Avruch, 2009, Amino acid regulation of TOR complex 1, Am. J. Physiol. Endocrinol. Metab., 296, E592, 10.1152/ajpendo.90645.2008 Fang, 2001, Phosphatidic acid-mediated mitogenic activation of mTOR signaling, Science, 294, 1942, 10.1126/science.1066015 Foster, 2007, Regulation of mTOR by phosphatidic acid?, Cancer Res., 67, 1, 10.1158/0008-5472.CAN-06-3016 Sun, 2008, mTOR signaling: PLD takes center stage, Cell Cycle, 7, 3118, 10.4161/cc.7.20.6881 Toschi, 2009, Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin, Mol. Cell. Biol., 29, 1411, 10.1128/MCB.00782-08 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Foster, 2009, Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells, Biochim. Biophys. Acta, 1791, 949, 10.1016/j.bbalip.2009.02.009 Zetterberg, 1995, What is the restriction point?, Curr. Opin. Cell Biol., 7, 835, 10.1016/0955-0674(95)80067-0 Foster, 2010, Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s), Genes Cancer, 1, 1124, 10.1177/1947601910392989 Fingar, 2004, mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E, Mol. Cell. Biol., 24, 200, 10.1128/MCB.24.1.200-216.2004 Gadir, 2008, Defective TGF-beta signaling sensitizes human cancer cells to rapamycin, Oncogene, 27, 1055, 10.1038/sj.onc.1210721 Ward, 2012, Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate, Cancer Cell, 21, 297, 10.1016/j.ccr.2012.02.014 Blagosklonny, 2011, Molecular damage in cancer: an argument for mTOR-driven aging, Aging, 3, 1130, 10.18632/aging.100422 Hardt, 2011, Activating mutations of TOR (target of rapamycin), Genes Cells, 16, 141, 10.1111/j.1365-2443.2010.01482.x Leto, 2012, Regulation of glucose transport by insulin: traffic control of GLUT4, Nat. Rev. Mol. Cell Biol., 13, 383, 10.1038/nrm3351 Warburg, 1956, On respiratory impairment in cancer cells, Science, 124, 269, 10.1126/science.124.3215.269 Cantor, 2012, Cancer cell metabolism: one hallmark, many faces, Cancer Discov., 2, 881, 10.1158/2159-8290.CD-12-0345 Chen, 2003, Phospholipase D confers rapamycin resistance in human breast cancer cells, Oncogene, 22, 3937, 10.1038/sj.onc.1206565 Dall’Armi, 2010, The phospholipase D1 pathway modulates macroautophagy, Nat. Commun., 1, 142, 10.1038/ncomms1144 Thielmann, 2012, Redundant functions of phospholipases D1 and D2 in platelet alpha-granule release, J. Thromb. Haemost., 10.1111/j.1538-7836.2012.04924.x Guertin, 2006, Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt–FOXO and PKCα, but not S6K1, Dev. Cell, 11, 859, 10.1016/j.devcel.2006.10.007 Gangloff, 2004, Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development, Mol. Cell. Biol., 24, 9508, 10.1128/MCB.24.21.9508-9516.2004 Athenstaedt, 1999, Phosphatidic acid, a key intermediate in lipid metabolism, Eur. J. Biochem., 266, 1, 10.1046/j.1432-1327.1999.00822.x Wendel, 2009, Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis, Biochim. Biophys. Acta, 1791, 501, 10.1016/j.bbalip.2008.10.010 Rincon, 2012, Diacylglycerol kinase ζ: at the crossroads of lipid signaling and protein complex organization, Prog. Lipid Res., 51, 1, 10.1016/j.plipres.2011.10.001 Merida, 2008, Diacylglycerol kinases: at the hub of cell signalling, Biochem. J., 409, 1, 10.1042/BJ20071040 Tang, 2006, Identification of a novel human lysophosphatidic acid acyltransferase, LPAAT-theta, which activates mTOR pathway, J. Biochem. Mol. Biol., 39, 626, 10.5483/BMBRep.2006.39.5.626 Avila-Flores, 2005, Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid, J. Biol. Chem., 280, 10091, 10.1074/jbc.M412296200 Takita, 2011, Diacylglycerol kinase inhibitor R59022-induced autophagy and apoptosis in the neuronal cell line NG108-15, Arch. Biochem. Biophys., 509, 197, 10.1016/j.abb.2011.02.007 Gorentla, 2011, Negative regulation of mTOR activation by diacylglycerol kinases, Blood, 117, 4022, 10.1182/blood-2010-08-300731 Coon, 2003, Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells, Mol. Cancer Ther., 2, 1067 Bobrovnikova-Marjon, 2012, PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation, Mol. Cell. Biol., 32, 2268, 10.1128/MCB.00063-12 Hetz, 2012, The unfolded protein response: controlling cell fate decisions under ER stress and beyond, Nat. Rev. Mol. Cell Biol., 13, 89, 10.1038/nrm3270 Ozcan, 2008, Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis, Mol. Cell, 29, 541, 10.1016/j.molcel.2007.12.023 DeBerardinis, 2008, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation, Cell Metab., 7, 11, 10.1016/j.cmet.2007.10.002 DeBerardinis, 2008, Brick by brick: metabolism and tumor cell growth, Curr. Opin. Genet. Dev., 18, 54, 10.1016/j.gde.2008.02.003 Toschi, 2010, Phospholipase D–mTOR requirement for the Warburg effect in human cancer cells, Cancer Lett., 299, 72, 10.1016/j.canlet.2010.08.006 Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230, 10.1038/nature06734 Hitosugi, 2009, Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth, Sci. Signal., 2, ra73, 10.1126/scisignal.2000431 Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Possemato, 2011, Functional genomics reveal that the serine synthesis pathway is essential in breast cancer, Nature, 476, 346, 10.1038/nature10350 Gruning, 2011, Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells, Cell Metab., 14, 415, 10.1016/j.cmet.2011.06.017 Russo, 2009, Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention, Biochem. Pharmacol., 77, 937, 10.1016/j.bcp.2008.10.020 Sardesai, 1992, The essential fatty acids, Nutr. Clin. Pract., 7, 179, 10.1177/0115426592007004179 Zhang, 2012, Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling, Proc. Natl. Acad. Sci. U.S.A., 109, 1667, 10.1073/pnas.1110730109 Yoon, 2011, Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect, J. Biol. Chem., 286, 29568, 10.1074/jbc.M111.262816 Xu, 2011, Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1), J. Biol. Chem., 286, 25477, 10.1074/jbc.M111.249631 Yoon, 2011, Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway, J. Cell Biol., 195, 435, 10.1083/jcb.201107033 Veverka, 2008, Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR, Oncogene, 27, 585, 10.1038/sj.onc.1210693 Rodriguez Camargo, 2012, The FKBP–rapamycin binding domain of human TOR undergoes strong conformational changes in the presence of membrane mimetics with and without the regulator phosphatidic acid, Biochemistry, 51, 4909, 10.1021/bi3002133 Bjorklund, 2006, Identification of pathways regulating cell size and cell-cycle progression by RNAi, Nature, 439, 1009, 10.1038/nature04469 Ray, 2011, Phospholipase D controls Dictyostelium development by regulating G protein signaling, Cell. Signal., 23, 335, 10.1016/j.cellsig.2010.09.017 Rosel, 2012, TOR complex 2 (TORC2) in Dictyostelium suppresses phagocytic nutrient capture independently of TORC1-mediated nutrient sensing, J. Cell Sci., 125, 37, 10.1242/jcs.077040 Ghosh, 2003, Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase: mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos, J. Biol. Chem., 278, 45690, 10.1074/jbc.M302933200 Goi, 2000, An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity, EMBO J., 19, 623, 10.1093/emboj/19.4.623 Jiang, 1995, Involvement of Ral GTPase in v-Src-induced phospholipase D activation, Nature, 378, 409, 10.1038/378409a0 Maehama, 2008, RalA functions as an indispensable signal mediator for the nutrient-sensing system, J. Biol. Chem., 283, 35053, 10.1074/jbc.M805822200 Wiczer, 2012, Phospholipase D and mTORC1: nutrients are what bring them together, Sci. Signal., 5, pe13, 10.1126/scisignal.2003019 Zhong, 2003, Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells, Biochem. Biophys. Res. Commun., 302, 615, 10.1016/S0006-291X(03)00229-8 Chen, 2005, Alternative phospholipase D/mTOR survival signal in human breast cancer cells, Oncogene, 24, 672, 10.1038/sj.onc.1208099 Rodrik, 2005, Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc, Mol. Cell. Biol., 25, 7917, 10.1128/MCB.25.17.7917-7925.2005 Rodrik, 2006, Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells, FEBS Lett., 580, 5647, 10.1016/j.febslet.2006.09.013 Hui, 2005, mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells, J. Biol. Chem., 280, 35829, 10.1074/jbc.M504192200 Zheng, 2006, Phospholipase D couples survival and migration signals in stress response of human cancer cells, J. Biol. Chem., 281, 15862, 10.1074/jbc.M600660200 Shi, 2007, Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras, Cancer Lett., 258, 268, 10.1016/j.canlet.2007.09.003 Garcia, 2008, Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells, Clin. Cancer Res., 14, 4267, 10.1158/1078-0432.CCR-08-0102 Wolf, 2007, Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest, Int. J. Oncol., 30, 1529 Lavieri, 2010, Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor, J. Med. Chem., 53, 6706, 10.1021/jm100814g Lewis, 2009, Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity, Bioorg. Med. Chem. Lett., 19, 1916, 10.1016/j.bmcl.2009.02.057 Lavieri, 2009, Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity, Bioorg. Med. Chem. Lett., 19, 2240, 10.1016/j.bmcl.2009.02.125 Menendez, 2007, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat. Rev. Cancer, 7, 763, 10.1038/nrc2222